RVA
Click for more information
0.00% 17.0¢ reva medical, inc

Ann: REVA Announces Positive 24-Month Clinical Results, page-2

  1. Neyepudete22
    824 Posts.
    lightbulb Created with Sketch. 44
    clock Created with Sketch.
    24/05/18
    20:47
    Post #: 33298315
    The 2-year results from the FANTOM II trial are very promising for REVA Medical's (RVA) Fantom bioresorbable scaffold, which offers advantages relative to first generation bioresorbable scaffolds such as a thinner strut profile and x-ray visibility. According to the company, the data indicate that Fantom’s advantages are translating into positive outcomes for patients

    http://crweworld.com/article/news-p...ar-results-show-sustained-safety-and-efficacy
    RVA Price at posting: 29.5¢ Sentiment: None Disclosure: Not Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

BGL Bellevue aims for 45% production increase by FY 2028, announces $150M placement
right-arrow Created with Sketch.
IGO IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
right-arrow Created with Sketch.
NEWS Capital raisings wrap: Brainchip, Ovanti, Lake and VHM
right-arrow Created with Sketch.
MIN MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned
right-arrow Created with Sketch.
TRP Tissue Repairs soars nearly 32% on TGA approval for wound healing gel
right-arrow Created with Sketch.
NEWS Real estate dynamics & changes raise investor doubt
right-arrow Created with Sketch.
watchlist Created with Sketch. Add RVA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.